Esperion Therapeutics, Inc. (ESPR) Stock Price

ESPRStock
$3.1881.48%52W
Market Cap$819.46M
P/E
PEG Ratio
Div yield
Beta-0.27

ESPR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.79%
Price vs S&P 500 (4W)-1.38%
VGM Score55.62

ESPR Earnings Surprise History

Q2 25-0.02est. -0.16
Q3 25-0.16est. -0.08
Q4 250.22est. 0.28
Q1 26-0.10est. -0.03

ESPR Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.93
2.55
2.55
2.55

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ESPREsperion Therapeutics, Inc.
CBC$3.18
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Esperion Therapeutics, Inc.

Esperion Therapeutics develops and commercializes oral, once-daily non-statin therapies for patients with elevated LDL cholesterol. The company's portfolio includes NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, providing accessible alternatives to traditional statins. Esperion focuses on addressing the significant patient population requiring innovative lipid management solutions.